Tuberculosis Diagnostics Global Market Report 2024

The tuberculosis diagnostics market size has grown strongly in recent years. It will grow from $2.11 billion in 2023 to $2.27 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The expansion observed during the historical period can be attributed to several factors. These include an increase in tuberculosis cases, higher healthcare spending, a rise in the number of healthcare facilities, and increased adoption of nucleic acid testing methods.

The tuberculosis diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.02 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. Forecasted growth is driven by strong government support, increased FDA approvals for TB diagnostics, growing R&D, and the emergence of drug-resistant TB. Key trends include NGS platform adoption, product innovations, T cell tests, AI integration, portable device use, and government-manufacturer collaborations.

The surge in tuberculosis cases is a key driver behind the escalating demand for tuberculosis diagnostics, underscoring the market's growth trajectory. Tuberculosis, an infectious respiratory disease, poses a significant health threat and spreads through airborne particles released during coughing and sneezing. Tuberculosis diagnostics play a crucial role in the early detection and diagnosis of the disease. A notable example of this trend is evident in the Centers for Disease Control and Prevention's weekly report in March 2022, revealing a 9.4% increase in tuberculosis infections in the United States in 2021. The total reported cases reached 7,860, compared to 7,173 cases in the preceding year. Consequently, the rising incidence of tuberculosis is a key factor propelling the expansion of the tuberculosis diagnostics market.

The growing number of approvals from the US Food and Drug Administration (FDA) for tuberculosis diagnostics will further bolster market growth. An illustrative instance is the announcement made in March 2023 by PerkinElmer Oxford Immunotec, a UK-based medical diagnostics company, regarding the FDA approval for the use of two additional cell isolation instruments, Auto-Pure 24 and Auto-Pure 20B platforms, manufactured by Allsheng Instruments. Additionally, in October 2022, PerkinElmer Oxford Immunotec received FDA approval for the use of the T-Cell Select reagent kit, facilitating the automation of the T-SPOT.TB test workflow for in vitro diagnostic (IVD) use by certified laboratories. T-Cell Select, a peripheral blood mononuclear cell (PBMC) isolation reagent, employs positive selection of PBMCs with magnetic bead-based cell separation to streamline the preparation of cells for the T-SPOT.TB test - an internationally regulated ELISPOT IGRA designed for detecting latent tuberculosis infection. This influx of FDA approvals for novel tuberculosis diagnostics is anticipated to reinforce and drive the growth of the tuberculosis diagnostics market.

The prevailing trend shaping the tuberculosis diagnostics market is the adoption of technological innovations, with major market players actively integrating advanced technologies to maintain their market standing. Notably, companies are introducing sophisticated point-of-care (POC) diagnostic methods leveraging artificial intelligence (AI) technology. A case in point is the collaboration between Fujifilm, a Japan-based medical imaging device manufacturer, and Qure.AI, a US-based company specializing in AI-enabled medical imaging solutions. In August 2022, they jointly launched an advanced POC diagnostic method utilizing a battery-powered X-ray machine for tuberculosis diagnosis. The integration of artificial intelligence algorithms enhances testing programs, offering ultra-portability, high accuracy, and efficient solutions for point-of-care diagnostics.

A prominent trend in the tuberculosis diagnostics market is the emphasis on product innovations as companies strive to remain competitive and meet evolving consumer needs and preferences. Product innovation plays a pivotal role in generating enthusiasm, driving sales, and increasing brand awareness. Companies in the tuberculosis diagnostics sector are actively focusing on developing new product solutions to fortify their market positions. A noteworthy example is Redcliffe Labs, an India-based technology-empowered diagnostics service provider, which, in February 2023, introduced the BD MAX MDR TB (Tuberculosis) test. This diagnostic test, performed on the BD MAX molecular diagnostic system, enables clinicians to rapidly test for tuberculosis and multidrug resistance as a first-line test. Clinicians use the test to simultaneously detect bacteria causing TB and ascertain whether the bacteria exhibit mutations associated with resistance to two vital first-line drugs, Isoniazid (INH) and Rifampicin (RIF). This focus on product innovation is integral to strengthening companies' positions within the tuberculosis diagnostics market.

In March 2021, PerkinElmer, a US diagnostics and scientific research company, acquired Oxford Immunotec for $591 million. This strategic move enables PerkinElmer to broaden its portfolio of infectious disease testing solutions, particularly enhancing tuberculosis detection capabilities, catering to a global clientele. Oxford Immunotec, a UK-based company specializing in proprietary assays for immunology and infectious diseases, strengthens PerkinElmer's position in this critical sector.

Major companies operating in the tuberculosis diagnostics market report are Beckton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Qiagen N.V, BioMerieux SA, Danaher Corporation, PerkinElmer, Thermo Fisher Scientific Inc., Creative Diagnostics, Lionex GmbH, Biocartis, Bio-Techne India Private Limited, Bio-Rad laboratories India Pvt.Ltd., Zhejiang Di'an Diagnostics Technology Co., Ltd., ADICON Clinical Laboratories, Guangzhou Kingmed Diagnostics Center Co. Ltd., Kindstar Global, OriGene Technologies, Siemens AG, Fresenius, Koninklijke Philips, Novartis, LumiraDx Limited, TestLine Clinical Diagnostics s.r.o., Hologic, Bayer AG, Cantel Medical Corporation, Meridian Bioscience, Johnson & Johnson, Abbott laboratories Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, Pfizer, Agilent technologies Inc, AutoGenomics, AdvaCare Pharma, Akonni Biosystems Inc, Par Pharmaceutical, Epistem Limited, Gen-Probe, Sysmex South Africa (Pty) Ltd., Grifols S.A., Bio Certica, Biovac, BixBio.

Asia-Pacific was the largest region in the tuberculosis diagnostics market in 2023. The regions covered in the tuberculosis diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tuberculosis diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The tuberculosis diagnostics market comprises various types of tests such as radiographic testing, laboratory testing, nucleic acid testing, cytokine detection testing, drug resistance testing, skin test (TST)/Mantoux test, blood/serology tests, smear microscopy tests, cell culture-based tests, and other methods. Radiographic tests are utilized to identify chest abnormalities indicative of tuberculosis symptoms. These tests focus on diagnosing lesions that can manifest anywhere in the lungs, differing in cavitation, density, size, and shape. These diagnostic methods encompass nucleic acid testing (NAT), skin testing or Mantoux test (TST), blood testing or serology tests, smear microscopy, cultured-based tests, radiography tests, and other approaches. They serve various disease stages such as latent tuberculosis and active tuberculosis. End-users of tuberculosis diagnostics include hospitals, diagnostic laboratories, physician’s office laboratories, reference laboratories, academic institutions, and research facilities.

The tuberculosis diagnostics market research report is one of a series of new reports that provides tuberculosis diagnostics market statistics, including tuberculosis diagnostics industry global market size, regional shares, competitors with a tuberculosis diagnostics market share, detailed tuberculosis diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the tuberculosis diagnostics industry. This tuberculosis diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tuberculosis diagnostics market includes revenues earned by entities by providing services related to diagnostic laboratory methods, detection of latent infection, detection of drug resistance, and diagnostic laboratory testings. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.